143 related articles for article (PubMed ID: 30530749)
1. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
Mohanty A; Sandoval N; Phan A; Nguyen TV; Chen RW; Budde E; Mei M; Popplewell L; Pham LV; Kwak LW; Weisenburger DD; Rosen ST; Chan WC; Müschen M; Ngo VN
Blood; 2019 Jan; 133(4):306-318. PubMed ID: 30530749
[TBL] [Abstract][Full Text] [Related]
2. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141
[TBL] [Abstract][Full Text] [Related]
3. Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.
Chuang WY; Chang H; Shih LY; Lin TC; Yeh CJ; Ueng SH; Kuo MC; Kao HW; Liu H; Chang ST; Lee CL; Huang KP; Wang TH; Wan YL; Yu JS; Hsueh C; Chuang SS
Virchows Arch; 2024 May; ():. PubMed ID: 38733379
[TBL] [Abstract][Full Text] [Related]
4. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Li S; Tang G; Jain P; Lin P; Xu J; Miranda RN; Cheng J; Yin CC; You MJ; Wang ML; Medeiros LJ
Mod Pathol; 2024 Feb; 37(2):100405. PubMed ID: 38104893
[TBL] [Abstract][Full Text] [Related]
5. Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement.
Tan L; Bansal G; Yeung CC; Yin J; Dave BJ; Konnick E; Wu D; Naresh KN
Ann Hematol; 2024 Feb; 103(2):667-669. PubMed ID: 37882866
[No Abstract] [Full Text] [Related]
6. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for etiology and prognosis of mantle cell lymphoma.
Wang Y; Ma S
Expert Rev Hematol; 2014 Apr; 7(2):233-43. PubMed ID: 24559208
[TBL] [Abstract][Full Text] [Related]
8. SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features.
Sureda-Gómez M; Iaccarino I; De Bolòs A; Meyer MA; Balsas P; Richter J; Rodríguez ML; López C; Carreras-Caballé M; Glaser S; Nadeu F; Jares P; Siciliano MC; Bellan C; Tornambè S; Boccacci R; Clot G; Leoncini L; Campo E; Siebert R; Amador V; Klapper W
Blood; 2024 Apr; ():. PubMed ID: 38620074
[TBL] [Abstract][Full Text] [Related]
9. Short report: Behavioural characterisation of SOX11 syndrome.
Al-Jawahiri R; Stokes L; Smith H; McNeill A; Freeth M
Res Dev Disabil; 2023 Dec; 143():104623. PubMed ID: 37924570
[TBL] [Abstract][Full Text] [Related]
10. Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
Blood; 2023 Sep; 142(13):1173-1176. PubMed ID: 37768692
[No Abstract] [Full Text] [Related]
11.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Lin RJ; Ho C; Hilden PD; Barker JN; Giralt SA; Hamlin PA; Jakubowski AA; Castro-Malaspina HR; Robinson KS; Papadopoulos EB; Perales MA; Sauter CS
Br J Haematol; 2019 Mar; 184(6):1006-1010. PubMed ID: 30537212
[TBL] [Abstract][Full Text] [Related]
13. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Dobrovolsky D; Wang ES; Morrow S; Leahy C; Faust T; Nowak RP; Donovan KA; Yang G; Li Z; Fischer ES; Treon SP; Weinstock DM; Gray NS
Blood; 2019 Feb; 133(9):952-961. PubMed ID: 30545835
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7H3.
Zhu XW; Wang J; Zhu MX; Wang YF; Yang SY; Ke XY
Biochem Biophys Res Commun; 2019 Jan; 508(4):1067-1073. PubMed ID: 30553455
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
von Keudell G; Younes A
Br J Haematol; 2019 Jan; 184(1):105-112. PubMed ID: 30536386
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
Rule S; Cook G; Russell NH; Hunter A; Robinson S; Morley N; Sureda A; Patrick P; Clifton-Hadley L; Adedayo T; Kirkwood A; Peggs KS
Br J Haematol; 2019 Mar; 184(6):999-1005. PubMed ID: 30560573
[TBL] [Abstract][Full Text] [Related]
18. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
[TBL] [Abstract][Full Text] [Related]
19. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
von Tresckow J; Cramer P; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Illmer T; Klaproth H; Estenfelder S; Ritgen M; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst BF; Hallek M
Leukemia; 2019 May; 33(5):1161-1172. PubMed ID: 30568174
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,
Chu Y; Lee S; Shah T; Yin C; Barth M; Miles RR; Ayello J; Morris E; Harrison L; Van de Ven C; Galardy P; Goldman SC; Lim MS; Hermiston M; McAllister-Lucas LM; Giulino-Roth L; Perkins SL; Cairo MS
Oncoimmunology; 2019; 8(1):e1512455. PubMed ID: 30546948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]